The value of 18F-fluorodeoxyglucose-positron emission tomography/ computed tomography (18F- FDG PET/CT) in the staging and impact on the management of patients with nasopharyngeal carcinoma by Subha, Sethu Thakachy et al.
Pertanika J. Sci. & Technol. 25 (3): 687 - 696 (2017)
SCIENCE & TECHNOLOGY
Journal homepage: http://www.pertanika.upm.edu.my/
ISSN: 0128-7680  © 2017 Universiti Putra Malaysia Press.
Article history:
Received: 2 February 2016
Accepted: 5 December 2016
E-mail addresses: 
subhast2@yahoo.com (Sethu Thakachy Subha), 
ahmadsaadff@gmail.com; ainurff@gmail.com  
(Fathinul Fikri Ahmad Saad), 
drimaging@yahoo.com; abdjalil@upm.edu.my  
(Abdul Jalil Nordin), 
drsaraiza@yahoo.com (Saraiza Abu Bakar) 
*Corresponding Author
The value of 18F-fluorodeoxyglucose –positron emission tomography/
computed tomography (18F- FDG PET/CT) in the staging and impact 
on the management of patients with nasopharyngeal carcinoma 
Sethu Thakachy Subha1*, Fathinul Fikri Ahmad Saad2, Abdul Jalil Nordin2 and 
Saraiza Abu Bakar3
1Department of Surgery/ENT, Faculty Medicine and Health Sciences, University Putra Malaysia,  
43400 UPM, Serdang, Selangor, Malaysia
2Centre for Diagnostic Nuclear Imaging, University Putra Malaysia, 43400 UPM, Serdang, Selangor, Malaysia
3Department of ENT, Hospital Serdang, 43000 Serdang, Selangor, Malaysia
ABSTRACT
This study sought to prospectively evaluate the influence of contrasted fluorine-18 fluorodeoxyglucose 
positron emission tomography/computed tomography (18F-FDGPET/CT) in the staging of and impact 
on the management plan for treatment in patients with nasopharyngeal carcinoma (NPC). A total of 
14 histologically proven NPC patients (mean age: 44.64±4.01years) were included in the study. These 
patients underwent contrasted Computed Tomography (CT) as well as 18F-FDGPET/CT imaging. Staging 
was based on the 7th edition of the American Joint Committee on Cancer Tumor Node Metastases (AJCC-
TNM) recommendations.The oncologist was asked to prospectively assign a treatment plan for all patients 
being evaluated by CT and 18F-FDGPET/CT. The treatment plans were compared with the incremental 
information supplied by the FDG-PET/CT. The maximum standardised uptake value (SUVmax) and 
the widest dimension of the primary tumour, cervical lymph nodes size and the distant metastatic 
lesions were quantified on the co-registered PET/CT images by two experienced nuclear radiologists. 
The contrasted 18F-FDGPET/CT  changed the management intent in nine patients (64.7%). A univariate 
analysis showed that there were significant correlations between SUVmax and the size of the metastatic 
lymph nodes (R2 =0.0761, p<0.01), lymph node volume (R2=0.695, p<0.01) and the T-stage (R2=0.647, 
p<0.01). Multiple linear regression analysis revealed the tumour SUVmax to be the independent predictor 
of the T-stage (adjusted R2=0.889, p<0.05). The 
SUVmax may potentially be a surrogate marker for 
the T-stage in the NPC patients. The use of the 
combined imaging modality, 18F-FDGPET/CT, 
substantially impacted on the management 
strategy for treatment of NPC patients.  
Keywords: 18F-FDG PET/CT, nasopharyngeal 
carcinoma, AJCC-TNM staging), SUVmax, impact 
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INTRODUCTION
Nasopharyngeal carcinoma (NPC) is unique and distinguished from other head and neck 
malignant tumours because of its epidemiology, histopathological spectrum, clinical 
characteristics, therapy and biological behavior (Vokes et al., 2000; Yang et al., 2015). 
Distinct geographic variation in the incidence of NPC indicates an influence of genetic and 
environmental factors. Various reports revealed that the southern Chinese are an ethnically 
distinct and high-risk group for this particular tumour.The environmental factor is the ingestion 
of Cantonese-style salted fish especially in childhood. NPC presents most commonly as a neck 
lump in 50% to 70% of patients as a result of cervical lymph node metastases. The tumour 
may not be clinically apparent at the time of presentation (Goh et al., 2009). The symptoms 
are usually protracted and the disease manifests late in its course. 
Positron Emission Tomography (PET) imaging has been reported to be the more sensitive 
imaging technique in detecting clinically occult metastatic disease, retropharyngeal lymph 
nodes, small volume lesions and distant metastases (Chang et al., 2005; Fathinul et al., 
2009). The use of a glucose analogue (fluorodeoxyglucose, FDG) underpins the cancer cell 
reprogramming on the altered glycolytic metabolism, seen as areas of increased tracer uptake 
on the PET images. The standardised uptake value (SUV) is a measure of the FDG-intensity 
on the PET image and appears to be a reliable parameter in evaluating correlation with factors 
that determine the tumour’s aggressiveness (Fathinul et al., 2013). All NPC cases in this study 
were regrouped into two histological types according to the WHO 1991 classification, namely 
keratinising squamous cell carcinoma (equivalent to WHO Type I) and non-keratinising 
carcinoma (pooling together WHO Type II non-keratinising and Type III undifferentiated 
carcinoma in the old terminology (Shanmugaratnam et al., 1991).
Although the five-year survival rate for overall NPC patients is high, around 90% of 
patients with distant metastases will die within one year (King et al., 2000). Thus, accurate 
staging and restaging of NPC are important for improving treatment and prognosis. As outlined 
by the AJCC (American Joint Committee on Cancer), the TNM staging system is the most 
important prognostic factor for appropriate treatment planning and survival prediction of NPC 
patients (Li et al., 2014). A revised AJCC-TNM staging 7th edition was released in 2009. 
There were several revisions in the new edition staging system compared to 6th edition. Li et 
al. compared the prognostic value of the TNM 6th edition and the TNM 7th edition for NPC 
patients. Their study demonstrated that the TNM 7th staging system is superior to the TNM 
6th staging system in predicting the frequency of overall survival and distant metastases free 
survival (Li et al., 2014).  
The superiority of the PET/CT to whole-body MRI in overall TNM staging supports the 
usefulness of 18F-FDG PET/CT as a possible first-line modality for whole-body tumour staging 
(Antoch et al., 2003). The N stage was found to be prognostically significant even among 
patient groups stratified for the size and degree of fixation of the neck nodes involved (Antoch 
et al., 2003; Chen et al., 2007). Though irrelevant to the N staging of NPC, the SUVmax was 
correlated to the size of the lymph nodes and also related to the degree of differentiation of NPC 
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(Liu et al., 2012). Analysing the prognostic factors for nasopharyngeal carcinoma (Iacovelli et 
al., 2014) demonstrated that the most significant prognostic factors in nasopharyngeal carcinoma 
were patient age, T-stage of the primary tumour, presence of cervical lymphadenopathy and 
certain technical factors of irradiation. This study was set to evaluate the clinical application 
of FDG PET/CT in predicting the staging of NPC using SUV on the latest AJCC 7th edition 
and to determine its potential impact on the management strategy for treatment.
MATERIALS AND METHODS
Patient Accrual
This study was approved by the institutional ethical committee and obtained written consent 
from all the patients .We prospectively analysed the contrasted CT and 18F-FDGPET/CT 
findings from 14 consecutive patients (mean age: 44.64±4.01) with histologically proven 
NPC. The exclusion criteria were children, acute or chronic inflammatory disease, pregnant 
patients, lactating mothers, terminally ill patients and any previous malignancy. Staging of the 
disease was done based on the 7th edition AJCC-TNM (American Joint Committee on Cancer-
Tumor size, Lymph Nodes, Metastases) staging system based on both imaging modalities. The 
oncologist was asked to outline the patients’ treatment management intent based on CT as well 
after PET/CT. The change in management intent and incremental information obtained after 
PET/CT imaging were compared and analysed.
 
18F-FDG-PET/CT
All the subjects were required to fast for at least 6 hours prior to PET/CT, although oral 
hydration with glucose-free water was allowed. After verification of a normal blood glucose 
level in the peripheral blood (mean FBS), patients received an IV injection of 370 MBq (10 
mCi) of FDG and then rested for approximately 60 minutes prior to the PET/CT imaging. 
Image acquisition was performed with an integrated PET/CT device (Siemens Biograph-64) 
consisting of a PET scanner (lutetium oxyorthosilicate) 64-MDCT scanner. The axes of both 
systems were aligned such that the patient could be moved from the CT scanner to the PET 
scanner with a movement of the examination table of up to 68 cm. Patients were allowed normal 
shallow respiration during acquisition of CT scan. The CT was performed with IV contrast 
(Iopamidol 300) at 5.0-mm spiral acquisition from base of skull to the proximal thigh for the 
purpose of anatomical localisation and attenuation correction to rescale the FDG-PET image 
attenuation. The PET emission was performed contemporaneously at 3 minutes per bed position 
acquisition. CT data were resized from a 512 × 512 matrix to a 128 × 128 matrix to match the 
PET data to allow image fusion and CT transmission maps were generated. PET image data 
sets were reconstructed iteratively with the ordered-subsets expectation maximisation algorithm 
with segmented measured attenuation correction (two iterations, 28 subsets) with the CT data. 
Co-registered images were displayed on the Siemens-Leonardo workstation. 
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Image Analysis
The SUVmax and the widest dimension of the primary tumour, size of the cervical lymph nodes 
and the distant metastatic lesions were quantified on the co-registered PET/CT images by two 
experienced nuclear radiologists who were blinded to the diagnosis. As for the CT, nodes 
with a short-axis diameter greater than 10 mm were defined as abnormal, and the presence of 
necrosis within a lymph node was considered a sign of malignancy, regardless of node size. 
STATISTICS
Mean, SD, range and frequencies were used to describe the data. Differences in the mean of 
the variables were analysed via a non-parametric test (Kruskal Wallis) The clinical risk factors 
i.e. age, sex, SUVmax and tumour size were evaluated for independent predictors for the TNM 
staging (AJCC 7th edition) using the univariate and multivariate analysis. A two-sided p value 
of <0.05 was considered significant.
RESULTS
Patients Characteristics
Fourteen patients with nasopharyngeal carcinoma were included in this study with the mean 
age of 44.64± 4.01 years. They comprised four females and 10 males. Biopsy results were 
available for all patients with WHO (type 1) noted in one patient and WHO (type II) in the 13 
others (Table 1). All the patients had pre-treatment CT and 18F-FDG PET/CT for the purpose 
of TNM staging disease stratification for the intended management plan (Table 2).
Out of the 14 patients, five had early-stage disease (Stage I and Stage II) and of them, two 
were put on an altered treatment plan based on the PET-CT results. Nine patients were initially 
classified as having advanced stage disease (Stage III and Stage IV) and seven of these patients 
had their treatment altered following the findings of the PET-CT inaging. The PET-CT imaging 
accurately identified that the extension of the primary tumour and T staging had changed in the 
four patients. The PET-CT imaging had correctly identified the nodal stage in three patients and 
these patients benefitted by being having neoadjuvant chemotherapy added. Distant metastases 
were identified in four patients and thus, the management intent was changed from definitive 
to palliative intent. Nine (64.3%) patients had stage migration i.e. upstaging of the disease as 
shown in Table 3.There was no change in disease staging among five of the (35.3%) patients.
Table 1
Patient Characteristics
Parameter Characteristic n %
Age 44.64±4.01 (years)
Sex
Male 10 71.42
Female 4 28.57
Histology
WHO (Type 1) 1 7.14
WHO (Type 1I) 13 92.85
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Table 2
Management Intent Based On CT and PET-CT
No age sex
CT 
staging  
PET/CT staging Management Intent
CT PET/CT
P1 44 M
T1N3M0
IVB
T1N3bM0
IVB
3 cycles 
neoadj Ct 
then CtRT
3 cycles neoadj Ct then CtRT
P2 56 F
T1N2M0
III
T1N3bM0
IVB
CtRT 3 cycles neoadj Ct then CtRT
P3 50 M
T2N1M0
II
T4N1M0
IVA
CtRT 3 cycles neoadj Ct then CtRT
P4 70 M
T1N0M0
I
T1N0M0
I
RT alone RT alone
P5 39 M
T2N2M0
III
T4N2M0
IVA
CtRT 3 cycles neoadj Ct then CtRT
P6 22 M
T1N1M0
I
T1N1M0
I
CtRT CtRT
P7 65 M
T3N2M0
III
T3N3M0
IVB
CtRT 3 cycles neoadj Ct then CtRT
P8 46 M
T3N0M0
III
T4N0M1
IVC
CtRT Chemotherapy – 6 cycles
P9 42 M
T3N3M0
IVB
T4N1M0
IVA
3 cycles 
neoadj Ct 
then CtRT
3 cycles neoadj Ct then CtRT
P10 55 F
T3N0M0
III
T4N0M1
IVC
CtRT Chemotherapy – 6 cycles
P11 54 M
T2N2M0
III
T2N2M1
IVC
CtRT Chemotherapy – 6 cycles
P12 22 M
T1N1M0
I
T2N1M0
II
CtRT CtRT
P13 26 F
T2N2M0
III
T2N2M0
III
CtRT CtRT
P14 34 F
T3N3M0
IVB
T3N3M1
IVC
3 cycles 
neoadj Ct 
then CtRT
Chemotherapy – 6 cycles
Note. NPC: Nasopharyngeal Carcinoma; CT: Computed Tomography; 
PET/CT: Positron Emission Tomography/Computed Tomography; 
RT: Radiotherapy; Ct: Chemotherapy; neoadj: neoadjuvant
CtRT: Chemoradiotherapy
M-male, F-Female
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Table 3
Influence of PET-CT Findings on the Impact of Management Intent
Number of 
patients
Stage Migration/
shift
Management 
intent with  CT
Management intent 
with PET/ CT
Impact on 
management intent
2 11 -1VA CtRT Neoadj Ct &CtRT High
3 111-1V B CtRT Neoadj CT &CtRT High
3 111 -1VC CtRT Chemotherapy alone High
1 1VB-1VC Neoadj Ct &CtRT Chemotherapy alone High
CT: Computed Tomography; PET/CT: Positron Emission 
Tomography/Computed Tomography; RT: Radiotherapy; Ct: Chemotherapy
neoadj: neoadjuvant; CtRT: Chemoradiotherapy
Correlation of SUVmax and the Clinical Risk Parameters
As shown in Table 4, the univariate analysis showed significant correlations between SUVmax of 
the primary tumour and the widest diameter of metastatic lymph nodes (R2=0.0.761, p<0.01) 
and the lymph node volume (R2=0.695, p<0.01). There was no significant correlation with 
other continuous clinical risk parameters pertaining to the primary tumour with the SUVmax. 
Table 4
Univariate Analysis of SUVmax Primary Tumour for Clinical Risk Variables
SUVmax   mean 14.28±2.43
Clinical parameter/R2
Mean P value
Lymph node size (d/cm) 1.14±0.09 <0.01
Lymph node volume (cm3) 3.05±0.47 <0.01
SUVmax as a Predictive Marker
Multiple linear regression analysis revealed the tumour SUVmax to be the independent predictor 
of the T-stage (adjusted R2=0.889, p<0.05). There was no influence of the other clinical 
parameters on the SUVmax. The details of these are shown in the Table 5.
Table 5
Multivariate Analysis of the SUVmax for the Clinical Risk Variables (n=14)
Clinical parameter HR (95% CI) p
Age 0.433 ± 0.315 0.711
Sex 22.217±  11.19 0.450
Lymph node size 44.420± 10.23 0.177
No of lymph node 1.808±  1.94 0.931
T stage 11.564± 0.17 *0.045
N stage 6.167± 7.38 0.833
M stage 18.085± 13.14 0.712
* Statistical significant value (p<0.05)
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DISCUSSION
Nasopharyngeal carcinoma is a progressive epithelial malignancy that is often under-staged 
by clinical examination (Chen et al., 2006). Accurate timely diagnosis of TNM staging is of 
paramount importance for appropriate treatment planning and prognosis (Zeng et al., 2014). The 
main effective method of treatment for NPC is radiotherapy and a good outcome is indicated 
if the disease is detected early in its course. The five-year overall survival rate is about 50% 
to 70% (Phua et al., 2013). 
As shown in our study, the SUVmax for this diseases is significantly correlated with the 
size and the volume of the metastatic lymph nodes. These indicate that SUVmax as a marker 
for an altered glucose metabolism is an important signalling marker of the PET that reflects 
the tumour aggressiveness. This evidence clearly shows that the prevalence of the nodal 
metastasis is proportionally associated with tumour aggressiveness as reflected on the TNM 
staging. Information gathered from PET imaging complements the questionable sub-centimeter 
lymph node that is vastly imperceptible on the CT. This was reflected in our study and is seen in 
Table 2 (P2, P7& P9) which shows that the patients were upstaged based on the N-stage. This 
is in line with previous reports that stated that FDG PET-CT has higher accuracy in detecting 
cervical Lymph nodes than conventional imaging (Chang et al., 2005).
SUVmax was determined to be the only independent parameter for the T-staging. The 
finding further emphasised that the aggressiveness of the primary tumour was reflected by 
the intensity of the SUVmax concentration of the primary tumour. In this context, SUVmax 
plays a potential role in T-staging as determined in our study. This is in accordance with other 
reports that established the association of 18F-FDG PET/CT on the T staging of NPC (Phua 
et al., 2013). Chen et al. compared 18F-FDG PET/CT, PET and CT in the detection of the 
primary site of NPC and reported that the T stage was accurately determined in 18 out of 20 
cases with 18F-FDG PET/CT. Both PET alone and CT alone correctly assessed the T-stage in 
15 out of 20 cases (Chen et al., 2006).
The SUVmax was found to be a statistically insignificant marker for the M staging in our 
cohort of patients compared with those in other reports, which stated the contrary in other 
cancer cell lines. The explanation for this is that our study cohort included a small number of 
patients, in whom the PET findings were positive for metastatic disease. There were only four 
patients (P8, P10, P11 and P14) who were found to have positive metastatic deposits on PET 
but none was discerned from the CT. Although no correlation was found between the SUVmax 
and the M-staging, it is noteworthy to highlight that PET had accurately detected two patients 
with skeletal metastasis on the FDG-PET. This is supported by the study by Liu et al., whose 
report showed that 18F-FDG PET was more sensitive in detecting bone metastases compared 
to skeletal scintigraphy (Liu et al., 2006). Two patients in our study group were detected to 
have mediastinal nodal metastases by PET/CT. The treatment for all four patients with distant 
metastases was subsequently altered to palliative intent.
Our 18F FDG PET/CT study findings had altered the management intent of 64.7% [9/14] 
patients based on the TNM-AJCC 7th edition. Among them, the PET /CT findings disclosed 
further evidence of distant metastases in 28% [4/14] patients. This study suggested 18F-FDG 
uptake as measured by SUVmax in the PET-CT could potentially play a significant role in 
providing appropriate staging and adequate treatment planning.
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Limitations
There were some limitations to our study. Some of the influence of the SUVmax did not seem 
to influence clinical parameters as stated in other studies. The potential attribute for this may 
be due to the small sample size calculated for a significant statistical test. A more cohesive 
method in preparing the patients for the PET-CT scanning and the scanning procedures should 
be adopted as to minimise factors that lead to image degradation. This was observed when the 
scanning time varied from 45 minutes to 90 minutes and some of the suboptimal images were 
not repeated to yield an image of better quality. It would also have had been better to include 
an MRI study in the comparative analysis with the CT imaging as the former is known to have 
better soft tissue resolution than the latter, thus providing better image interpretation.
CONCLUSION
While the SUVmax may potentially be a surrogate marker for the T-stage in NPC patients 
based on the 7th edition of AJCC-TNM staging, the use of the contrasted 18[F]-FDGPET/CT 
substantially impacted on the management strategy for treatment of the disease.
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